Publication: Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection
Issued Date
2017-10-18
Resource Type
ISSN
15292916
15292908
15292908
DOI
Other identifier(s)
2-s2.0-85031797326
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Nature Immunology. Vol.18, No.11 (2017), 1261-1269
Suggested Citation
Estefania Fernandez, Wanwisa Dejnirattisai, Bin Cao, Suzanne M. Scheaffer, Piyada Supasa, Wiyada Wongwiwat, Prabagaran Esakky, Andrea Drury, Juthathip Mongkolsapaya, Kelle H. Moley, Indira U. Mysorekar, Gavin R. Screaton, Michael S. Diamond Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection. Nature Immunology. Vol.18, No.11 (2017), 1261-1269. doi:10.1038/ni.3849 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/42693
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection
Abstract
© 2017 Nature America, Inc., part of Springer Nature. All rights reserved. The Zika virus (ZIKV) epidemic has resulted in congenital abnormalities in fetuses and neonates. Although some cross-reactive dengue virus (DENV)-specific antibodies can enhance ZIKV infection in mice, those recognizing the DENV E-dimer epitope (EDE) can neutralize ZIKV infection in cell culture. We evaluated the therapeutic activity of human monoclonal antibodies to DENV EDE for their ability to control ZIKV infection in the brains, testes, placentas, and fetuses of mice. A single dose of the EDE1-B10 antibody given 3 d after ZIKV infection protected against lethality, reduced ZIKV levels in brains and testes, and preserved sperm counts. In pregnant mice, wild-type or engineered LALA variants of EDE1-B10, which cannot engage Fcg receptors, diminished ZIKV burden in maternal and fetal tissues, and protected against fetal demise. Because neutralizing antibodies to EDE have therapeutic potential against ZIKV, in addition to their established inhibitory effects against DENV, it may be possible to develop therapies that control disease caused by both viruses.